Current News

Contact | Print version | PDF version | Send article | RSS feed

ImmunoVaccine Technologies Broadens Its Patent Protection to Japan

07 Aug 2008 - ImmunoVaccine Technologies Inc. (IVT) announced receipt of patent approval from the Japanese Patent Office for its vaccine platform. The specific patent, Vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.
 
Securing broad patent coverage is part of IVT's strategy to maximize the market potential of its VacciMax® platform in the largest pharmaceutical markets in the world; including the US, Europe, Canada, Australia and Japan. The company's VacciMax® technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax® technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination. The responses are also long lasting, without requiring booster immunizations.